Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Lopategui on the Use of Liquid Biopsies in Lung Cancer

February 21st 2020

Jean Lopategui, MD, discusses the use of liquid biopsies in lung cancer.

Dr. Denduluri on the Use of the Oncotype DX Assay in Early-Stage HR+/HER2- Breast Cancer

February 21st 2020

Neelima Denduluri, MD, discusses the use of the Oncotype DX assay in early-stage hormone receptor–positive, HER2-negative breast cancer.

HER2+ Breast Cancer Treatment Arsenal Expands With ADCs

February 20th 2020

Sara A. Hurvitz, MD, Neelima Denduluri, MD, and Madelaine Kuiper, MSN, RN, discuss the rise of HER2-targeted therapies and their implications on the field.

Homing in on Targeted Treatment Strategies in Breast Cancer

February 20th 2020

Neelima Denduluri, MD, sheds light on the use of genomic assays in early-stage HR-positive/HER2-negative breast cancer, as well as the agents that are prolonging survival in patients with metastatic HER2-positive disease.

Dr. Husain on Liquid Biopsy Versus Tissue Biopsy in NSCLC

February 20th 2020

Hatim Husain, MD, discusses the utility of liquid biopsy versus tissue biopsy in non–small cell lung cancer.

Dr. Luke on Predictive Biomarkers in Metastatic Melanoma

February 20th 2020

Jason J. Luke, MD, FACP, discusses predictive biomarkers in metastatic melanoma.

Dr. Levy on Repeat Testing in NSCLC

February 20th 2020

Benjamin P. Levy, MD, discusses the importance of repeat testing in non–small cell lung cancer.

Molecular Testing Essential in NSCLC Management

February 19th 2020

Jean Lopategui, MD, reflects on the use of molecular testing for patients with non–small cell lung cancer.

Dr. Cercek on the Impact of Tumor Sidedness on Frontline Treatment in mCRC

February 19th 2020

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the impact of tumor sidedness on frontline treatment decisions in metastatic colorectal cancer (mCRC).

Multiomic Screening Modality Shows Promise in Early-Stage CRC

February 17th 2020

Girish Putcha, MD, PhD, provides insight on the study results and highlights the advantages of using a multiomic, blood-based assay in colorectal cancer screening.

Molecular Markers Critical to Guiding Treatment in Newly Diagnosed mCRC

February 17th 2020

Andrea Cercek, MD, shares insight on treatment selection, the importance of molecular testing, and unanswered questions with tumor sidedness in patients with newly diagnosed metastatic colorectal cancer.

Dr. Putcha on the Results of the AI EMERGE Trial in CRC

February 14th 2020

Girish Putcha, MD, PhD, discusses the results of the AI EMERGE trial (NCT03688906) in colorectal cancer.

Dr. Eward on the Unmet Need for Novel Agents for TGCT and Sarcoma

February 14th 2020

William Eward, MD, DVM, discusses the unmet need for novel agents in tenosynovial giant cell tumor and sarcoma.

Dr. Bardia on the Clinical Utility of Liquid Biopsies in Breast Cancer

February 12th 2020

Aditya Bardia, MD, MPH, discusses the clinical utility of liquid biopsies in breast cancer.

Dr. Levy on Ongoing Research Evaluating the Use of Liquid Biopsies in Lung Cancer

February 8th 2020

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses ongoing research regarding the use of liquid biopsies in lung cancer.

Dr. Putcha on Blood-Based Detection of Early-Stage CRC

February 6th 2020

Girish Putcha, MD, PhD, chief medical officer and clinical laboratory director, Freenome, discusses blood-based detection of early-stage colorectal cancer (CRC) using multiomics and machine learning.

Perseverance Is the Name of the Game With HER3 Research in Solid Tumors

February 5th 2020

Despite a reasonable expectation that expression of HER3 and its ligand heregulin would be predictive biomarkers for HER3-targeted therapy, their usefulness in clinical trials has been hit-and-miss. Nevertheless, investigators have persevered, and new types of drugs have largely supplanted the first generation in clinical trials.

The Search for Biomarkers in Metastatic Breast Cancer

February 5th 2020

James M. Reuben, PhD, MBA, discusses the search for biomarkers in patients with metastatic breast cancer.

Potential Immunotherapy Response Markers Emerge in Metastatic Breast Cancer

February 4th 2020

James M. Reuben, PhD, MBA, discusses his research on using liquid biopsies to identify predictive biomarkers for immunotherapy in patients with metastatic breast cancer.

Expert Outlines Next Steps for Liquid Biopsies in Oncology

February 4th 2020

Benjamin P. Levy, MD, discusses the next steps with liquid biopsies in non–small cell lung cancer and its broader use in oncology.